2020
Substance Use Disorder Detection Rates Among Providers of General Medical Inpatients
Serowik KL, Yonkers KA, Gilstad-Hayden K, Forray A, Zimbrean P, Martino S. Substance Use Disorder Detection Rates Among Providers of General Medical Inpatients. Journal Of General Internal Medicine 2020, 36: 668-675. PMID: 33111239, PMCID: PMC7947066, DOI: 10.1007/s11606-020-06319-7.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersMedical inpatientsPatient characteristicsMedical recordsGeneral medical inpatient unitsPatient self-report questionnairesGeneral medical inpatientsMedical inpatient unitsOpioid use disorderDrug use disordersNicotine use disorderPatients' medical recordsCannabis use disorderLarge teaching hospitalAlcohol use disorderDetection rateCocaine use disorderWhite patientsBlack patientsFemale patientsHispanic patientsFormal screeningInpatient providersTeaching hospital
2014
Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study
Yonkers KA, Forray A, Nich C, Carroll KM, Hine C, Merry BC, Shaw H, Shaw J, Sofuoglu M. Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study. The Lancet Psychiatry 2014, 1: 360-367. PMID: 25328863, PMCID: PMC4199242, DOI: 10.1016/s2215-0366(14)70333-5.Peer-Reviewed Original ResearchCocaine use disorderCocaine usePostpartum womenPost trialUse disordersPlacebo-controlled pilot trialOral micronized progesteronePositive urine testPost-partum womenGroup differencesSelf-reported daysMultiple brain functionsUse of cocaineMicronized progesteroneObstetrical clinicTherapeutic breakProgesterone replacementAdverse eventsUS National InstitutesProgesterone treatmentUrine testsPilot trialRate of submissionStudy biostatisticianProgesterone